According to a new study in Cancer Epidemiology Biomarkers & Prevention, brisk walking or vigorous exercise may help reduce risk of breast cancer in African-American women.
According to a new study in Cancer Epidemiology Biomarkers & Prevention, brisk walking or vigorous exercise may help reduce risk of breast cancer in African-American women.
Researchers from Boston University’s Slone Epidemiology Center used prospective data from the Black Women’s Health Study on 44,708 African-American women aged 30 years or older at the time of enrollment to assess vigorous exercise in relation to the overall incidence of invasive breast cancer (n = 1364), estrogen receptor-positive cancer (n = 688), and estrogen receptor(ER)-negative cancer (n =405). More than 307,672 person years of follow-up were studied and Cox proportional hazards models were used to estimated incidence rate ratios (IRR) and 95% confidence intervals (CI).
Editorial: What's next with the morcellation controversy?
Vigorous exercise at baseline and brisk walking for at least 7 hours per week were inversely associated with overall breast cancer incidence (P trend = 0.05):the IRR for ≥7 hour/week relative to <1 hour/week was 0.74 (95% CI 0.57-0.96). ER status had no impact on the association. Breast cancer incidence was not associated with vigorous exercise in high school or at ages 21 or 30. Interestingly, significant periods of inactivity, such as watching television or sitting for long periods while at work, were not significantly associated with breast cancer incidence.
Investigators concluded that a high level of vigorous exercise could be associated with a reduced incidence of breast cancer in African-American women. They believe that the findings could provide information on a potentially modifiable risk factor.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More